Cargando…

QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus

OBJECTIVE: 10-year cardiovascular disease (CVD) risk scores are calculated using algorithms, including Framingham (worldwide) and QRISK2 (UK). Recently, an updated QRISK3 model was introduced, which considers new variables including SLE and steroid prescription, not included in QRISK2 and Framingham...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Nicola, Langford-Smith, Alexander W W, Parker, Benjamin J, Bruce, Ian N, Reynolds, John A, Alexander, M Yvonne, McCarthy, Eoghan M, Wilkinson, Fiona L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109811/ https://www.ncbi.nlm.nih.gov/pubmed/30167314 http://dx.doi.org/10.1136/lupus-2018-000272

Ejemplares similares

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus
por: Vázquez-Del Mercado, Mónica, et al.
Publicado: (2018)

Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk
por: Edwards, Nicola, et al.
Publicado: (2018)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
por: Carrillo-Palau, Marta, et al.
Publicado: (2021)

Cardiovascular risk quantification using QRISK-3 score in people with intellectual disability
por: Ho, Jamie Sin Ying, et al.
Publicado: (2021)

Pediatric systemic lupus erythematosus: Retrospective analysis of clinico-laboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score
por: Nazri, Siti Khadijah S.M., et al.
Publicado: (2018)

Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress
por: Mahmoud, Ayman M., et al.
Publicado: (2017)

Genetic load in incomplete lupus erythematosus
por: Slief, Matt, et al.
Publicado: (2023)

Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus
por: Reynolds, John A., et al.
Publicado: (2016)

Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
por: Parker, Ben, et al.
Publicado: (2014)

Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study
por: Livingstone, Shona J., et al.
Publicado: (2022)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus
por: Mu, Xiaodie, et al.
Publicado: (2022)

Systemic lupus erythematosus and cardiovascular disease
por: Ruilope, Luis M., et al.
Publicado: (2020)

An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study
por: Collins, Gary S, et al.
Publicado: (2009)

Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank
por: Parsons, Ruth E, et al.
Publicado: (2023)

Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women's Experiences Living with Lupus Study
por: Bridges, John, et al.
Publicado: (2022)

Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study
por: Livingstone, Shona, et al.
Publicado: (2021)

A Case of Capecitabine-Induced Discoid Lupus Erythematosus
por: Heo, Ji Hye, et al.
Publicado: (2020)

Systemic lupus erythematosus nephritis and COVID-19 disease
por: Gayathri, C., et al.
Publicado: (2023)

Anti‐retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis
por: Goules, Andreas, et al.
Publicado: (2019)

An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study
por: Collins, Gary S, et al.
Publicado: (2010)

Systemic Lupus Erythematosus and Cardiovascular Disease
por: Jha, Surajkumar B, et al.
Publicado: (2022)

Cardiovascular Complications in Systemic Lupus Erythematosus
por: Alghareeb, Rahmah, et al.
Publicado: (2022)

Cardiovascular Disease in Systemic Lupus Erythematosus
por: McMahon, Maureen, et al.
Publicado: (2021)

Systemic lupus erythematosus and cardiovascular disease
por: Frostegård, Johan
Publicado: (2022)

Factors Associated With Variation in Pediatric Systemic Lupus Erythematosus Care Delivery
por: Burnham, Jon M., et al.
Publicado: (2021)

Genetic epidemiology: Systemic lupus erythematosus
por: Ahmad, Yasmeen A, et al.
Publicado: (2001)

Neonatal Lupus Erythematosus
por: Lun Hon, Kam, et al.
Publicado: (2012)

Prediction of Cardiovascular Risk Using Framingham, ASSIGN and QRISK2: How Well Do They Predict Individual Rather than Population Risk?
por: van Staa, Tjeerd-Pieter, et al.
Publicado: (2014)

Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries
por: Izmirly, Peter M, et al.
Publicado: (2021)

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2
por: Collins, Gary S, et al.
Publicado: (2012)

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
por: Hippisley-Cox, Julia, et al.
Publicado: (2017)

The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus—A Pilot Study
por: Király, Zsófia, et al.
Publicado: (2023)

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
por: Reynolds, John A, et al.
Publicado: (2022)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Discoid lupus erythematosus in Iraqi patients: a clinical and histopathological study
por: Al-Hattab, Mohammed Kadhim, et al.
Publicado: (2004)

Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus
por: Petrovic, Gordana, et al.
Publicado: (2023)

Clinical analysis of patients with systemic lupus erythematosus complicated with liver failure
por: Zhang, Lili, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hs7d7l1lnd80mt44jdb2605jng